Dupixent is back on top as the pharma brand that took home the most TV impressions in May, according to data released by iSpot.tv on Thursday morning. Regeneron and Sanofi’s eczema and asthma ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...

With $17 billion in annual sales, Dupixent is a franchise drug for its 50/50 owners Sanofi and Regeneron Pharmaceuticals. So rivals have lined up to challenge the antibody treatment against autoimmune ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® ...

"Chiesi drops COPD and asthma asset after Phase III miss" was originally created and published by Clinical Trials Arena, a ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...